Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase

Nathan Erdmann, Jianxing Zhao, Alicia L. Lopez, Shelley Herek, Norman Curthoys, Terry D. Hexum, Takashi Tsukamoto, Dana Ferraris, Jialin C Zheng

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Mononuclear phagocyte (macrophages and microglia) dysfunction plays a significant role in the pathogenesis of human immunodeficiency virus (HIV) associated dementia (HAD) through the production and release of soluble neurotoxic factors including glutamate. The mechanism of glutamate regulation by HIV-1 infection remains unclear. In this report, we investigated whether the enzyme glutaminase is responsible for glutamate generation by HIV-1 infected monocyte-derived macrophages. We tested the functionality of novel small molecule inhibitors designed to specifically block the activity of glutaminase. Glutaminase inhibitors were first characterized in a kinetic assay with crude glutaminase from rat brain revealing an uncompetitive mechanism of inhibition. The inhibitors were then tested in vitro for their ability to prevent glutamate generation by HIV-infected macrophages, their effect upon macrophage viability, and HIV infection. To validate these findings, glutaminase specific siRNA was tested for its ability to prevent glutamate increase during infection. Our results show that both glutaminase specific small molecule inhibitors and glutaminase specific siRNA were effective at preventing increases in glutamate by HIV-1 infected macrophage. These findings support glutaminase as a potential component of the HAD pathogenic process and identify a possible therapeutic avenue for the treatment of neuroinflammatory states such as HAD.

Original languageEnglish (US)
Pages (from-to)539-549
Number of pages11
JournalJournal of Neurochemistry
Volume102
Issue number2
DOIs
StatePublished - Jul 1 2007

Fingerprint

Glutaminase
Macrophages
Viruses
HIV-1
Glutamic Acid
AIDS Dementia Complex
Aptitude
HIV
Virus Diseases
Small Interfering RNA
Molecules
Inhibition (Psychology)
Microglia
Phagocytes
Dementia
Rats
Assays
Brain
Kinetics

Keywords

  • Glutamate
  • Glutaminase
  • HIV-1-associated dementia
  • Macrophages

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. / Erdmann, Nathan; Zhao, Jianxing; Lopez, Alicia L.; Herek, Shelley; Curthoys, Norman; Hexum, Terry D.; Tsukamoto, Takashi; Ferraris, Dana; Zheng, Jialin C.

In: Journal of Neurochemistry, Vol. 102, No. 2, 01.07.2007, p. 539-549.

Research output: Contribution to journalArticle

Erdmann, N, Zhao, J, Lopez, AL, Herek, S, Curthoys, N, Hexum, TD, Tsukamoto, T, Ferraris, D & Zheng, JC 2007, 'Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase', Journal of Neurochemistry, vol. 102, no. 2, pp. 539-549. https://doi.org/10.1111/j.1471-4159.2007.04594.x
Erdmann, Nathan ; Zhao, Jianxing ; Lopez, Alicia L. ; Herek, Shelley ; Curthoys, Norman ; Hexum, Terry D. ; Tsukamoto, Takashi ; Ferraris, Dana ; Zheng, Jialin C. / Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. In: Journal of Neurochemistry. 2007 ; Vol. 102, No. 2. pp. 539-549.
@article{15c7f46516b04c789b7bed622619530f,
title = "Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase",
abstract = "Mononuclear phagocyte (macrophages and microglia) dysfunction plays a significant role in the pathogenesis of human immunodeficiency virus (HIV) associated dementia (HAD) through the production and release of soluble neurotoxic factors including glutamate. The mechanism of glutamate regulation by HIV-1 infection remains unclear. In this report, we investigated whether the enzyme glutaminase is responsible for glutamate generation by HIV-1 infected monocyte-derived macrophages. We tested the functionality of novel small molecule inhibitors designed to specifically block the activity of glutaminase. Glutaminase inhibitors were first characterized in a kinetic assay with crude glutaminase from rat brain revealing an uncompetitive mechanism of inhibition. The inhibitors were then tested in vitro for their ability to prevent glutamate generation by HIV-infected macrophages, their effect upon macrophage viability, and HIV infection. To validate these findings, glutaminase specific siRNA was tested for its ability to prevent glutamate increase during infection. Our results show that both glutaminase specific small molecule inhibitors and glutaminase specific siRNA were effective at preventing increases in glutamate by HIV-1 infected macrophage. These findings support glutaminase as a potential component of the HAD pathogenic process and identify a possible therapeutic avenue for the treatment of neuroinflammatory states such as HAD.",
keywords = "Glutamate, Glutaminase, HIV-1-associated dementia, Macrophages",
author = "Nathan Erdmann and Jianxing Zhao and Lopez, {Alicia L.} and Shelley Herek and Norman Curthoys and Hexum, {Terry D.} and Takashi Tsukamoto and Dana Ferraris and Zheng, {Jialin C}",
year = "2007",
month = "7",
day = "1",
doi = "10.1111/j.1471-4159.2007.04594.x",
language = "English (US)",
volume = "102",
pages = "539--549",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase

AU - Erdmann, Nathan

AU - Zhao, Jianxing

AU - Lopez, Alicia L.

AU - Herek, Shelley

AU - Curthoys, Norman

AU - Hexum, Terry D.

AU - Tsukamoto, Takashi

AU - Ferraris, Dana

AU - Zheng, Jialin C

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Mononuclear phagocyte (macrophages and microglia) dysfunction plays a significant role in the pathogenesis of human immunodeficiency virus (HIV) associated dementia (HAD) through the production and release of soluble neurotoxic factors including glutamate. The mechanism of glutamate regulation by HIV-1 infection remains unclear. In this report, we investigated whether the enzyme glutaminase is responsible for glutamate generation by HIV-1 infected monocyte-derived macrophages. We tested the functionality of novel small molecule inhibitors designed to specifically block the activity of glutaminase. Glutaminase inhibitors were first characterized in a kinetic assay with crude glutaminase from rat brain revealing an uncompetitive mechanism of inhibition. The inhibitors were then tested in vitro for their ability to prevent glutamate generation by HIV-infected macrophages, their effect upon macrophage viability, and HIV infection. To validate these findings, glutaminase specific siRNA was tested for its ability to prevent glutamate increase during infection. Our results show that both glutaminase specific small molecule inhibitors and glutaminase specific siRNA were effective at preventing increases in glutamate by HIV-1 infected macrophage. These findings support glutaminase as a potential component of the HAD pathogenic process and identify a possible therapeutic avenue for the treatment of neuroinflammatory states such as HAD.

AB - Mononuclear phagocyte (macrophages and microglia) dysfunction plays a significant role in the pathogenesis of human immunodeficiency virus (HIV) associated dementia (HAD) through the production and release of soluble neurotoxic factors including glutamate. The mechanism of glutamate regulation by HIV-1 infection remains unclear. In this report, we investigated whether the enzyme glutaminase is responsible for glutamate generation by HIV-1 infected monocyte-derived macrophages. We tested the functionality of novel small molecule inhibitors designed to specifically block the activity of glutaminase. Glutaminase inhibitors were first characterized in a kinetic assay with crude glutaminase from rat brain revealing an uncompetitive mechanism of inhibition. The inhibitors were then tested in vitro for their ability to prevent glutamate generation by HIV-infected macrophages, their effect upon macrophage viability, and HIV infection. To validate these findings, glutaminase specific siRNA was tested for its ability to prevent glutamate increase during infection. Our results show that both glutaminase specific small molecule inhibitors and glutaminase specific siRNA were effective at preventing increases in glutamate by HIV-1 infected macrophage. These findings support glutaminase as a potential component of the HAD pathogenic process and identify a possible therapeutic avenue for the treatment of neuroinflammatory states such as HAD.

KW - Glutamate

KW - Glutaminase

KW - HIV-1-associated dementia

KW - Macrophages

UR - http://www.scopus.com/inward/record.url?scp=34347225166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347225166&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2007.04594.x

DO - 10.1111/j.1471-4159.2007.04594.x

M3 - Article

VL - 102

SP - 539

EP - 549

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 2

ER -